Armata Pharmaceuticals, Inc. ARMP
We take great care to ensure that the data presented and summarized in this overview for Armata Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARMP
View all-
Bank Of America Corp Charlotte, NC634KShares$1.46 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA225KShares$518,1600.0% of portfolio
-
Geode Capital Management, LLC Boston, MA107KShares$246,2510.0% of portfolio
-
Edgewood Management LLC Greenwich, CT100KShares$229,9990.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX75.4KShares$173,3780.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny46.5KShares$106,9400.0% of portfolio
-
State Street Corp Boston, MA40.3KShares$92,6900.0% of portfolio
-
Sea Crest Wealth Management, LLC Purchase, NY35KShares$80,3940.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA29.8KShares$68,5070.0% of portfolio
-
Black Rock Inc. New York, NY22.9KShares$52,7180.0% of portfolio
Latest Institutional Activity in ARMP
Top Purchases
Top Sells
About ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Insider Transactions at ARMP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2024
|
Deborah Birx Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+18.75%
|
-
|
|
Mar 14
2024
|
Richard Rychlik Corporate Controller and PFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Dec 21
2023
|
Deborah Birx Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Mar 31
2022
|
Innoviva, Inc. Director |
BUY
Open market or private purchase
|
Indirect |
5,385,208
+24.76%
|
$26,926,040
$5.0 P/Share
|
|
Feb 09
2022
|
Innoviva, Inc. Director |
BUY
Open market or private purchase
|
Indirect |
3,614,792
+24.77%
|
$18,073,960
$5.0 P/Share
|
|
Oct 29
2021
|
Innoviva, Inc. Director |
BUY
Open market or private purchase
|
Indirect |
1,212,122
+14.13%
|
$3,636,366
$3.3 P/Share
|
|
Mar 17
2021
|
Innoviva, Inc. Director |
BUY
Open market or private purchase
|
Indirect |
4,285,935
+41.05%
|
$12,857,805
$3.25 P/Share
|
|
Jan 26
2021
|
Innoviva, Inc. Director |
BUY
Open market or private purchase
|
Indirect |
1,867,912
+50.0%
|
$5,603,736
$3.25 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 270K shares |
|---|